- Home
- NCTY vs KLRS Comparison
NCTY vs KLRS Comparison
Compare NCTY & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | KLRS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 44.5M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NCTY | KLRS |
|---|---|---|
| Price | $2.54 | $2.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 56.7K | ★ 58.1K |
| Earning Date | 11-24-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $1.78 |
| 52 Week High | $8.36 | $11.88 |
Technical Indicators
Market Signals| Indicator | NCTY | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 32.35 | 56.89 |
| Support Level | N/A | N/A |
| Resistance Level | $5.48 | $4.37 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 25.52 | 81.82 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Online game services, out of which Crypto mining business derives maximum revenue.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.